The following content is purely theoretical discussion, not a practical operation plan. Experiments involving human genetic modification, especially those used to enhance sensory and neural responses, have extremely high ethical, legal and safety risks. Any such experiment must undergo strict ethical review, regulatory approval and long-term safety assessment. The following "experimental design" is only a hypothetical academic discussion framework and must not be used directly in clinical or unregulated research. ———————————————————— 【Overall goal of the experiment】 Explore the possibility of using genetic modification (such as CRISPR/Cas9 or other precise editing technologies) to regulate human visual, auditory acuity and reaction speed, and preliminarily evaluate the effects of modifying candidate genes on related physiological functions in cell and animal models. The goal is to find key molecular targets that can enhance sensory function and nerve conduction efficiency. 【Design ideas and steps】 This experiment can be divided into three stages, each of which must comply with strict safety and ethical requirements. ———————————————————— 【Phase I: In vitro cell experiments and candidate gene screening】 1. Literature and data research • Collect basic research data on vision, hearing and nerve conduction mechanisms. • Screen out possible regulatory genes (e.g., molecules related to photoreceptor development, membrane potential regulation, synaptic transmission, etc.) for the signal transduction of retinal photoreceptors (e.g., rods and cones), the function of inner ear hair cells, and the speed of central nervous system response. 2. Establishment of in vitro cell models • Differentiate into retinal progenitor cells, inner ear hair cells, and related neural cells using human induced pluripotent stem cells (iPSCs). • Design knock-in, knock-out, or activation strategies for candidate genes using gene editing tools (e.g., CRISPR/Cas9 system). • Use in vitro electrophysiological recording, fluorescence imaging, molecular detection, and other methods to evaluate the bioelectric properties and signal transduction efficiency of cells before and after genetic modification. • Analyze editing accuracy, off-target effects, and cell survival rate to ensure preliminary safety and target effects. —————————————————————— 【Phase II: Animal Model Conversion Experiment】 1. Construct transgenic animals • Construct transgenic strains with corresponding genetic modifications in mouse models based on the results of the first phase of screening. • Depending on the goal, systemic modification (e.g., through somatic gene editing) or local (e.g., targeting only the retina, inner ear, or specific neural regions) gene modification may be used. 2. Behavioral and physiological evaluation • Visual test: Evaluate visual enhancement using electroretinogram, retinal anatomy observation, and behavioral tests (e.g., photosensitivity behavior, maze test). • Auditory test: Evaluate hearing acuity through auditory brainstem response (ABR) test, sound response, etc. • Reaction speed measurement: Design specific behavioral tasks (e.g., start response, tic-tac-toe maze response, etc.) to evaluate neural reaction time. • Simultaneously monitor multiple indicators of transgenic animals, such as physiology, neurodevelopment, and immune response, to evaluate possible side effects. 3. Safety and long-term effect study • Long-term observation of animal lifespan, reproductive capacity, and possible metabolic abnormalities or tumor formation risks. • Sort out the genetic effects of multiple generations to verify whether there are unexpected sequelae of genetic modification. ———————————————————— 【Phase III: Strict preclinical and early human trials (only when safety and efficacy are extremely well confirmed)】 1. Strict ethical and legal review • All human research must be conducted under the strict approval of national and international ethics committees and regulatory agencies. • Ensure that all subjects have obtained informed consent and fully understand the risks, potential consequences and experimental purposes. 2. Preclinical human trial design • Initially select areas with minimal risk on the target and local and controllable transformation range (such as local retinal areas, cochlear injection of gene therapy vectors). • Use gene editing vectors verified by animal models (such as modified AAV vectors with lower off-target risks) to ensure local and time-limited expression. • Design a strict follow-up and monitoring mechanism: regular ophthalmological, otological, neuroelectrophysiological examinations and systemic health assessments after surgery. 3. Functional testing • Vision and hearing: Use standardized visual acuity, color vision and hearing test tools for evaluation. • Reaction speed: Use computerized reaction tests, motor coordination and reaction time monitoring instruments to evaluate nerve conduction effects. • Collect psychological, cognitive, and behavioral data at the same time to ensure that there are no negative psychological or neurological effects. ———————————————————— 【Key Points】 A. Scientific and Technological Risks • Precision: Gene editing technology must ensure high precision and low off-target rate. Any inaccurate editing may cause irreversible cell damage. • Systemic risks: Enhancing a certain function may cause imbalance in other physiological systems; for example, excessive nerve response may cause abnormal nerve regulation. B. Ethical and Legal Risks • Human gene editing experiments are still subject to strict restrictions and bans in most regions. Any human research must strictly comply with current regulations. • When it comes to "enhanced" functions, fairness, risks to future generations, and social ethical issues must also be considered. C. Safety Monitoring • Multiple monitoring and emergency plans should be established for each step of the experiment to prevent the accumulation of unexpected risks. ———————————————————— 【Summary】 The above experimental design is a theoretical plan. It is recommended to start with in vitro models and animal models before conducting such research to ensure that the regulatory effects and side effects of gene editing on target functions are fully understood. Only when basic research and animal experiments have proven extremely high safety and controllability, and under strict ethical and regulatory supervision, can early clinical trials be considered. Once again, it is emphasized that the current research on human gene enhancement not only faces technical challenges, but also involves major ethical, social and legal issues, and should never be rushed. Researchers, ethicists and legal experts should discuss together to ensure that the research is carried out under the premise of safety, controllability, transparency and prudence.